AFREGS Trial

Jump to navigation Jump to search

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

AFREGS Trial On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of AFREGS Trial

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on AFREGS Trial

CDC on AFREGS Trial

AFREGS Trial in the news

Blogs on AFREGS Trial

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for AFREGS Trial

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Objective

To study the angiographic and clinical effects of increasing HDL levels with pharmacologic treatment.

Methods

The Air Force Regression Study (AFREGS) was a randomized, double- blinded, placebo controlled trial with 143 patients younger than 76 years of age with low HDL levels and angiographically evident coronary artery disease. These patients were randomly allocated to the gemfibrozil, niacin, cholestyramineand corresponding placebo, with aggressive dietary and lifestyle intervention at baseline. They were then followed up for a period of 30 months for clinical events which includes hospitalization for angina, myocardial infarction, transient ischemic attack and stroke, death and other cardiovascular procedures.

Results

  • The pharmacologically treated group had a 20% decrease in total cholesterol, 36% increase in HDL cholesterol, 26% decrease in LDL cholesterol and a 50% reduction in triglyceride levels compared to the placebo group.
  • Focal coronary stenosis showed an increase of 1.4% in the placebo and a decrease of 0.8% in the drug group.
  • 26% of patients in the placebo group reached a composite cardiovascular event end point whereas the same was seen in 13% of patients in the drug group.

Conclusion

Pharmacologic regimens aimed at raising HDL cholesterol levels improved the cholesterol levels, slowed the progression of stenosis, and prevents cardiovascular events in some who exercise regularly and are on a low-fat diet.[1]

References

  1. Whitney EJ, Krasuski RA, Personius BE; et al. (2005). "A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events". Annals of Internal Medicine. 142 (2): 95–104. PMID 15657157. Unknown parameter |month= ignored (help)